Merck & Co. Inc. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep.
Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies ...
A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that enough claimants have chosen to opt into the agreement.
Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others, company executives said Tuesday during a briefing on Merck's business.
Germany's Bayer plans to buy U.S.-based Merck & Co.'s consumer health business, creating a combined medicine cabinet of household names from Bayer's aspirin to Merck's Claritin allergy pills.
Major cost cuts enabled drugmaker Merck & Co. to offset lower first-quarter sales as generic competition continues to hurt sales of former blockbuster medicines. Merck's profit rose 7 percent, trouncing Wall Street expectations.
U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.
(HealthDay)—Merck will pay $100 million to settle thousands of lawsuits over the company's NuvaRing birth control device, according to insiders.
Merck & Co. reported a 14 percent decline in fourth-quarter profit as generic competition continued to cut into sales of one-time blockbuster medicines, and unfavorable currency exchange rates reduced overseas revenue.
Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada.
(HealthDay)—There may be good news coming in the form of a pill for the millions of Americans who suffer from ragweed allergy.
(HealthDay)—Packaging defects have prompted a recall of a combination cholesterol drug called Liptruzet, produced by Merck & Co., temporarily affecting the entire U.S. stock.
Forest Laboratories says it plans to cut $500 million in costs in about two years, and also plans to buy back up to $1 billion in company stock.
German chemicals and pharmaceuticals giant Merck KGaA said Thursday it is raising its full-year operating profit forecast thanks to improving sales and positive cost-cutting effects.